https://www.thebodypro.com/category/meeting-costs-hiv-care/tag/news-analysis

The Latest

close up of man's arm getting blood drawn

We Have a Cure for Hepatitis C. Why Are Rates So High?

An in-depth update on what we know about HCV risk, symptoms, screening, outcomes, and treatment (including financial barriers).

The DMV Balenciaga House Meeting

With Only 15% of Diagnosed HCV Patients Receiving Treatment, the Non-Profit I-MAK Hopes to Shift the National Conversation on Drug Pricing

The Initiative for Medicines, Access and Knowledge, Inc. (I-MAK) argues that the high price of hepatitis C cure medicines places them out of reach for most people.

Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say Img

Insurers and Pharmas Must Help Fix HIV Drug Pricing System, Advocates Say

The Fair Pricing Coalition is working with pharmaceutical companies to ensure fair prices for new HIV drugs on par with those of older medications.

The Need to Advocate for Fair HIV Drug Prices Img

The Need to Advocate for Fair HIV Drug Prices

"Drug prices are too high and your access to your drugs is in danger. So, wake up and get ready!" says Lynda Dee of the Fair Pricing Coalition.

1,000-Fold Mark-Up for Drug Prices in High Income Countries Blocks Access to HIV, HCV and Cancer Drugs Img

1,000-Fold Mark-Up for Drug Prices in High Income Countries Blocks Access to HIV, HCV and Cancer Drugs

An opening lecture at the 2016 Glasgow HIV Congress challenged the current model of drug pricing in high-income countries by showing mark-ups that are sometimes more than 1,000 times higher than production costs making many medicines largely unafford...

New Antiretrovirals Could Mean Savings Up to $3 Billion by 2025 Img

New Antiretrovirals Could Mean Savings Up to $3 Billion by 2025

The introduction of three new antiretrovirals into treatment programmes in low- and middle-income countries -- tenofovir alafenamide fumarate (TAF), low-dose efavirenz (Sustiva, Stocrin) and dolutegravir (Tivicay, DTG) -- could represent over $3 bill...

Potential Economic Impact of Dolutegravir/3TC Dual Therapy Img

Potential Economic Impact of Dolutegravir/3TC Dual Therapy

With cost driving so much in health care, the economic impact of a current experimental strategy might undermine the current dependence on three-drug combination therapy.

Sofosbuvir Access: New Patent Challenges to Sofosbuvir Img

Sofosbuvir Access: New Patent Challenges to Sofosbuvir

The ongoing struggle to enable access to sofosbuvir globally at affordable prices continues with several new developments.

With Trans-Pacific Partnership Looming, Over Half on HIV Meds in Vietnam Could Lose Access Img

With Trans-Pacific Partnership Looming, Over Half on HIV Meds in Vietnam Could Lose Access

One of the first studies to calculate how the draft trade agreement could affect people with HIV in resource-constrained settings notes that "similar price impacts can be expected for other countries participating in the [TPP], though these are less ...

International Activists Confront Gilead Over Hepatitis C Drug Pricing at AIDS 2014 Img

International Activists Confront Gilead Over Hepatitis C Drug Pricing at AIDS 2014

An international group of treatment activists interrupted a session at AIDS 2014 just as Gregg H. Alton, a top official at Gilead Sciences, was about to speak regarding the challenges of expanding global access to the new generation of hepatitis C dr...